Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 20, 2020

Imperial College advances Covid-19 vaccine into next phase

Imperial College London in the UK has advanced its Covid-19 vaccine candidate into the next phase of the COVAC1 clinical trial following the success in the initial dose escalation phase involving 15 volunteers.

Imperial College London in the UK has advanced its Covid-19 vaccine candidate into the next phase of the COVAC1 clinical trial following the success in the initial dose escalation phase involving 15 volunteers.

The latest phase of the study will enrol 105 participants aged 18-75 who will be given one of three doses of the vaccine candidate at a facility in west London. This first shot will be followed by a booster four weeks later.

Participants in the initial phase will also receive their second booster dose in the coming days.

The clinical team will track any potential adverse reactions, as well as test participants’ blood samples for the presence of neutralising antibodies against the SARS-CoV-2 virus, which causes Covid-19.

Imperial College London professor Robin Shattock said: “Analysing blood samples for antibodies and T-cell response will provide some indication of whether our vaccine can produce an immune response to fight the virus.

“Larger clinical trials will still be needed to tell us whether our vaccine candidate, and any other Covid-19 vaccine in development, may be successful in reducing the spread or severity of Covid-19.”

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Imperial College’s Covid-19 vaccine candidate is based on new self-amplifying RNA (saRNA) technology. It was subjected to preclinical studies and animal tests found the vaccine to be safe, with the potential to generate an effective immune response.

According to preclinical data published in Nature Communications journal, two doses of the vaccine were able to generate highly specific antibodies that could neutralise the virus in mice.

Imperial College started dosing participants in the COVAC1 trial last month.

The development and clinical trials of this Covid-19 vaccine candidate are supported by more than £40m in funding from the UK Government and additional financing in philanthropic donations.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU